2nd International Conference on PharmScience Research ... · Daniele Zink, NanoBio Lab (A*STAR),...
Transcript of 2nd International Conference on PharmScience Research ... · Daniele Zink, NanoBio Lab (A*STAR),...
UNITED Scientific Group
A non-profit organization
VenueFour Points by SheratonLos Angeles International Airport9750 Airport BoulevardLos Angeles, CA 90045United States
2ndInternational Conference on
PharmScience Research & Development
PHAR
MA R
&D-2
020
Feb
rua
ry 2
4-26
, 20
20
Program Overview
February
24Monday
07:30-08:00 Registrations and Badge Pickup
08:00-10:00 Keynote Session
10:00-10:15 Networking Break
10:15-12:55 Session I: Drug
12:55-13:25 Networking Lunch & Group Photo
13:30-16:05 Session I: Drug
16:05-16:20 Networking Break
16:20-17:40 Session I: Drug
February
26Wednesday
08:00-10:00 Session-III: Pharma Industry
10:00-10:15 Networking Break
10:15-11:55 Session-III: Pharma Industry
11:55-12:55 Session-IV: Formulations & Mechanisms
12:55-13:25 Networking Lunch
13:25-16:25 Session-IV: Formulations & Mechanisms
16:05- Departures
February
25Tuesday
07:40-10:00 Session-II: Pharmacology
10:00-10:15 Networking Break
10:15-12:55 Session-II: Pharmacology
12:55-13:25 Networking Lunch & Poster Setup
13:25-16:10 Session-II: Pharmacology
16:05-16:20 Networking Break & Poster Setup
16:20-17:40 Session-II: Pharmacology
17:40-18:30 Poster Session
Keynote Session
08:00-08:30 The Therapeutic Potential of GABA(A)ergic Subtype Selective Ligands James M Cook, University of Wisconsin Milwaukee, Milwaukee, WI
08:30-09:00 Nanomedicine: The New Effective Approach to Fighting Antimicrobial and Chemotherapeutic Resistance
Thomas Webster, Northeastern University, Boston, MA
09:00-09:30 What Research & Development Can Do to Rapidly (and Successfully) Commercialize New Biopharmaceutical Products
Mark F. Witcher, Independent Consultant, Chapel Hill, NC
09:30-10:00 Metadichol®. One Process Many Diseases, One Approach Many Possible Cures P.R. Raghavan, Nanorx Inc, Chappaqua, NY
10:00-10:15 Networking Break
Session-I: Drug
Drug Discovery | Drug Design | Drug Development | Drug Delivery
Chairs: To be Updated
10:15-10:35 Changing the Paradigm of Drug Target Discovery using FFPE Specimens from Colorectal Cancer Patients and Adaptive Dynamic Artificial Polyligand Targeting
Heather O’Neill, Caris Life Sciences, Phoenix, AZ
10:35-10:55 Multi-Functional Small Molecules as Novel Therapeutics for a Rare Pediatric Neurodegenerative Disease
Paul C. Trippier, University of Nebraska Medical Center, Omaha, NE
10:55-11:15 De novo Designed Amphipathic α-Helical Antimicrobial Peptides to Treat the Gram-Negative Pathogen, Acinetobacter baumannii
Robert S Hodges, University of Colorado, Aurora, CO
11:15-11:35 Nano-Enabled Cancer Immunotherapy using Immunogenic cell death and Reversing Immune Checkpoints
Jianqin Lu, The University of Arizona Health Sciences, Tucson, AZ
DAY
1 February 24, 2020
Note: Last minute changes due to functional, private, or organizational needs can be necessary.The event organizer accepts no liability for any additional costs caused by a change of program. Program
is subject to change
11:35-11:55 Validation of DPAGT1 Inhibitors for Anticancer Chemotherapeutics Michio Kurosu, University of Tennessee Health Science Center, Memphis, TN
11:55-12:15 In Situ Visualization of the Phase Separation in Amorphous Solid Dispersion Luxi Li, Argonne National Laboratory, Lemont, IL
12:15-12:35 Structural and Biochemical Studies on Trimethoprim Resistant DHFR from Pathogenic Bacteria
Dennis L Wright, University of Connecticut, Storrs, CT
12:35-12:55 Redesigning Oral Drugs for Inhalation: Drug Delivery Along The Roads Less Traveled Gustavo R Rosania, University of Michigan, Ann Arbor, MI
12:55-13:25 Networking Lunch
13:25-13:45 Liposome-Based Parenteral Drug Lyophilization: Design Strategies and Regulatory Guidance
Yuwei Wang, California Health Sciences University, Fresno, CA
13:45-14:05 Oral Films A Multi Faceted Drug Delivery System and Dosage Form Bhaumik Patel, Cure Pharmaceuticals, Los Angeles, CA
14:05-14:25 Extracellular Vesicles as Payload Carriers for Targeted Drug Delivery Marjo Yliperttula, University of Helsinki, Finland
14:25-14:45 Early Probe Discovery in Academia Anuradha Roy, The University of Kansas, Lawrence, KS
14:45-15:05 Multifunctional Drugs from Protein Conjugates Kurt Vesterager Gothelf, Aarhus University, Denmark
15:05-15:25 On Demand Drug Delivery Technique for Retinal Diseases and Glaucoma Jong-Ki Kim, Catholic University of Daegu, South Korea
15:25-15:45 Pyrazolo[4,3-e][1,2,4]triazine as a Promising Scaffold for New Drugs Due to its Versatile Biological Behavior
Mariusz Mojzych, Siedlce University of Natural Sciences and Humanities, Poland
15:45-16:05 Platinum-Gold Bimetallic Nanoparticles in Anticancer Drug Delivery Moganavelli Singh, University of KwaZulu-Natal, South Africa
16:05-16:20 Networking Break
16:20-16:40 Synergic Killing Superbugs by a Phytochemical Carvacrol and Blu Light Mei X. Wu, Harvard University, Boston, MA
16:40-17:00 Site-Specific Chemical Conjugation of Antibody Using Affinity Peptide for Development of Innovative Antibody Medicines
Yuji Ito, Kagoshima University, Japan
17:00-17:20 Using Integrative Analysis of DNA Methylation and Gene Expression Data in Multiple Tissue Types to Prioritize Candidate Genes for Drug Development in Obesity
Kiang Wei Kho, Dublin City University, Ireland
17:20-17:40 Quorum Sensing Inhibitors as Pathoblockers for Pseudomonas aeruginosa Infections: A New Concept in Anti-Infective Drug Discovery
Martin Empting, Helmholtz-Institute f. Pharmaceutical research saarland (HIPS), Germany
Session-II: Pharmacology
Chairs: Guofeng You, Rutgers University, Piscataway, NJ Concettina La Motta, University of Pisa, Italy
07:40-08:00 Ibudilast: A Novel Therapy Targeting Adipokines that Induce Insulin Resistance Cynthia B. Jones, Marshall University, Huntington, WV
08:00-08:20 Role of Cerebral Blood Autoregulation in Alzheimer-Like Dementia in Diabetes Fan Fan, The University of Mississippi Medical Center, Jackson, MS
08:20-08:40 Preclinical Testing of ICA-1; A Potent Protein Kinase C-ι Inhibitor as a Potential Anticancer Drug
Mildred Acevedo Duncan, University of South Florida, Tampa, FL
08:40-09:00 New Targets for Anti-Inflammatory Therapeutics; An Understudied Mechanism for Regulating Vascular Inflammation
Neil Grimsey, University of Georgia, Athens, GA
09:00-09:20 Clinical Pharmacology Considerations of Bispecific Antibodies Ping Ji, Food and Drug Administration, Silver Spring, MD
09:20-09:40 Targeting Oncogene and Inflammation Pathways for Cancer Therapy Ruiwen Zhang, University of Houston, Houston, TX
09:40-10:00 Development of Isoform-Selective Protein Arginine Methyltransferase Inhibitors Y George Zheng, University of Georgia, Athens, GA
10:00-10:15 Networking Break
10:15-10:35 Drug Resistance in Mycobacterium tuberculosis and Targeting the L,D-Transpeptidase Enzyme
Kottayil I.Varughese, University of Arkansas for Medical Sciences, Little Rock, AR
10:35-10:55 Are There Limitations to Exercise Benefits in Peripheral Arterial Disease? Robert Lust, East Carolina University, Greenville, NC
10:55-11:15 Adeno-Associated Virus Delivery of Compounds for Analgesia: Targeting Dorsal Root Ganglia
Hongwei Yu, Medical College of Wisconsin, Milwaukee, WI
11:15-11:35 Molecular Mechanisms Underlying the Regulation of Drug Transporters Guofeng You, Rutgers University, Piscataway, NJ
11:35-11:55 Central versus Peripheral Sites of Action of New Ghrelin Agonists on Gastrointestinal Prokinetic Activity
Ehsan N. Mohammadi, University of Oklahoma Health Science Center, Oklahoma, OK
11:55-12:15 Evaluation of Commercially Available Meth-Deterrent Pseudoephedrine Products Ziyaur Rahman, Texas A&M University, College Station, TX
DAY
2 February 25, 2020
12:15-12:35 Inhibitor Design for CRIF1-CDK2 Interface: Unprecedented Strategy to Osteosarcoma Cell Proliferation
Sheng-Xiang Lin, Laval University, Canada
12:35-12:55 Effects of the Adipokinetic Hormone/Red Pigment-Concentrating Hormone (AKH/RPCH) Family of Peptides on Rat Schizophrenia Models
Oguz Mutlu, Kocaeli University Medical Faculty, Turkey
12:55-13:25 Networking Lunch & Poster Setup
13:25-13:45 Small Molecule Agonists of Glial Cell Line-Derived Neurotrophic Factor Receptor RET for Disease Modification in Parkinson’s Disease and Neuropathic Pain
Yulia Sidorova, University of Helsinki, Finland
13:45-14:05 Histamine Antagonists in the Kidney: May they Manage the Diabetic Nephropathy? Arianna Carolina Rosa, University of Turin, Italy
14:05-14:25 In-Silico Design and Biological Investigations of Diabetic Neuropathy Modulators: Could MOR Become a Focal Mediator for this Pathology?
Simone Ronsisvalle, University of Catania, Italy
14:25-14:45 Aldehyde Dehydrogenase Inhibitors: the Challenge to Defeat Cancer Stem Cells Concettina La Motta, University of Pisa, Italy
14:45-15:05 MDesign and Development of Dual Malate Dehydrogenase (MDH) 1/2 Inhibitors Targeting Cancer Metabolism
Minkyoung Kim, Dongguk University, South Korea
15:05-15:25 Efficient and Accurate Prediction of Human Organ Toxicities Daniele Zink, NanoBio Lab(A*STAR), Singapore
15:25-15:45 Effects of Antiepileptic Drugs on Spontaneous Recurrent Seizures in a Novel Model of Extended Hippocampal Kindling in Mice
Liang Zhang, Krembil Research Institute, Canada
15:45-16:05 The NIH Microphysiological Systems Program: Organs on Chips for Drug Efficacy and Toxicity Studies
Danilo A.Tagle,National Institutes of Health, Bethesda MD
16:05-16:20 Networking Break
16:20-16:40 Activity of Silver Nanoparticles on Prokaryotic Cells and Bothrops jararacussu Snake Venom
Isadora Caruso Fontana Oliveira, University of Sorocaba, Brazil
16:40-17:00 Efficacy of Aerosolized Rifaximin Versus Tobramycin for the Treatment of Pseudomonas aeruginosa Pneumonia in Mice
Roy Al Ahmar, Marshall University, Huntington, WV
17:00-17:20 Design and Synthesis of 1,2-Bis(hydroxymethyl)pyrrolo[2,1-a]phthalazine Hybrids as Potent Anticancer Agents that Inhibit Angiogenesis and Induce DNA Interstrand Cross-links
Tai-Ling Chen, China Medical University, Taiwan
17:20-17:40 Role of IL-1B and IL-6 in Antiarrhythmic Effect of Atrovastatin in Ouabain-Induced Arrhythmia in Rats
Azam Bakhtiarian, Tehran University of Medical Sciences, Iran
17:40-18:00 Targeting Non-coding RNAs for Cancer Therapy Yangchao Chen, The Chinese University of Hong Kong, Hong Kong
17:40-18:30 Poster Session
P-01 Reduce Cardiac Injury in Diabetes: GLP-1 Agonists, SGLT2 Inhibitors or Combination Therapy? Zhao Li, University of Saint Joseph, Hartford, CT
P-02 Further Studies on the Neuroprotective Actions of Hydrogen Sulfide and Cannabinoids in the Bovine Isolated Retina
Sunny E. Ohia, Texas Southern University, Houston, TX
P-03 Synthesis, Evaluation and Computational Simulations of Novel Pyrimidine Analogs as BRD4 Inhibitors
Haeil Park, Kangwon National University, South Korea
P-04 Skin Immunization with Third-Generation Hepatitis B Surface Antigen Using Microneedle Kim Jiseok, Gachon University, South Korea
P-05 A Comparison of Efficacy and Toxicity Profile According to Docetaxel, Platinum, Fluoropyrimidine Therapy in Advanced Gastric or Gastroesophageal Adenocarcinoma: Systematic Review and Meta-Analysis
Kyung Soo Kim,The Catholic University of Korea, South Korea
P-06 Isolation and Characterization and in vitro Test of Lytic Bacteriophages Against Antibiotic-Resistant Bacterial Strains of Pseudomonas aeruginosa
Liliam Harada, University of Sorocaba, Brazil
P-07 Microneedle for Intradermal Delivery of Botulinum Toxin A to Treat Palmar Hyperhidrosis Oh Yu Jeong, Gachon University, South Korea
P-08 The Antimicrobial Activity of Camel Lactoferrin Peptide Saleh Mohammed Saeed Alamri, Prince Sultan Military Medical City, Saudi Arabia
P-09 Lipidomic Analysis of the Effects of Melittin on Ovarian Cancer Cells Using Mass Spectrometry Sanad Alonezi, Prince Sultan Military Medical City, Saudi Arabia
P-10 The Preparation of Influenza Vaccine Microneedles Using Low Temperature Manufacturing Process
Shin Yu Ra, Gachon University, South Korea
P-11 Polymeric Nanocapsules Loaded with Phloretin: Antimelanoma Study and Development of New Semisolid Formulation
Talita P A Casarini, Federal University of Rio Grande do Sul, Brazil
P-12 Deflazacort-Induced Acneiform Eruptions Mohammed Shakeel Mohammed Bashir, Taif University, Saudi Arabia
P-13 Protective Effect of Curcumin in HepG2 Cells Against the Possible Cytotoxicity of drugs with activity antifibrotic (Doxazosin, Carvedilol and Tamsulosin)
Mariana Yazmin Medina-Pizaño, Universidad Autónoma de Aguascalientes, Mexico
P-14 Preliminary Research on Antitumor Effects of Atomic Carbon Jufeng Xia, New Japan Medical Institute, Japan
P-15 Antibacterial Efficacy of Hibiscus Extracts, Method Standardization for Studying Bioactive Compounds
Carmen Nava-Fischer, St. Philip’s CollegeSan Antonio, TX
Session-III: Pharma Industry
Analysis | Vigilance & RA | Case Studies
Chairs: To be Updated
08:00-08:20 Real-World Evidence in Drug Development and Regulatory Submission Tze L Lai, Stanford University, Stanford, CA
08:20-08:40 Rapid Development of New Biopharmaceutical Products Using a Multi-Purpose Manufacturing Facility
Mark F. Witcher, Independent Consultant, Chapel Hill, NC
08:40-09:00 Using a Surrogate Marker for Early Testing of a Treatment Effect Layla Parast, RAND Corporation, Santa Monica, CA
09:00-09:20 Characterization of Protein and Silicone Particles in Therapeutic Formulations Using Imaging Flow Cytometry
Christine Probst, Luminex Corporation, Seattle, WA
09:20-09:40 The Certainty in Consumers Willingness to Accept Pharmacist Provided Medication Therapy Management Services
Lawrence “LB” Brown, Chapman University, Irvine, CA
09:40-10:00 A Novel Method using Nuclear Magnetic Resonance for Plasma Protein Binding Assessment in Drug Discovery Programs
Daniel Oscar Cicero, University of Rome Tor Vergata, Italy
10:00-10:15 Networking Break
10:15-10:35 A Case Study in Identifying Targeted Patients Population in Major Depressive Disorder by Enhanced Enrichment Design
Peter Zhang, Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ
10:35-10:55 Relative Group Contribution (RGC) Model as an Innovative Strategy for the Rescue of Small-Molecule Fragments in Drug Discovery
Andres Felipe Vasquez, Universidad de los Andes, Colombia
10:55-11:15 Adverse Drug Reaction Profile in Amravati Region of India- A Pharmacovigilance Study Mohammed Shakeel Mohammed Bashir,Taif University, Saudi Arabia
11:15-11:35 A Case Study in Addressing CHMP Major Objections in Efficacy to Achieve Registration Approval
John Ouyang, Otsuka Development & Commercialization Inc., Rockville, MD
11:35-11:55 Genotypic Characterization of Pseudomonas aeruginosa Isolates from Turkish Children with Cystic Fibrosis
Dicle Sener Okur, Istanbul University, Turkey
DAY
3 February 26, 2020
Session-IV: Formulations & Mechanisms
Natural Compounds | Nanomedicine | Personlized Medicine | Biopharmaceutics
Chairs: To be Updated
11:55-12:15 Pediatric Oral Formulations: An Updated Review of Commercially Available Pediatric Oral Formulations Since 2007
Robert G. Strickley, Pliant Therapeutics, San Francisco, CA
12:15-12:35 Evaluation of Anti Obesity Activity of Ethanolic Extract ofx1 Degener Leaves in 3T3- L1 Cell Lines
Jinitha Anu Saji, Caritas College of Pharmacy, India
12:35-12:55 Litogenolitic and Solubility Properties of Products Obtained from Common Ivy Extract (Hederae helicis e folium) and Medium of Diversified Polarity (ƐM)
Elzbieta Nowak, Europlant Group, Poland
12:55-13:25 Networking Lunch
13:25-13:45 Rapid Development of Nano-Formulations from Screening to Production Combining Dual Centrifugation DELTAVITA 1 and Wet Agitator Bead Milling
Dan Galvin, NETZSCH Premier Technologies, LLC., Exton, PA
13:45-14:05 Modeling Clearance of Immune Checkpoint Inhibitors as a Potential Biomarker for Drug Resistance in Mice
Mitch Phelps, The Ohio State University, Powell, OH
14:05-14:25 Innovative Technologies for Drying of Moist Porous Media Jamal Yagoobi, Worcester Polytechnic Institute, Worcester, MA
14:25-14:45 A New Mouthrinse Formula for Long Term Maintenance of Oral Hygiene Stephen Connelly, University of California, San Francisco, CA
14:45-15:05 Personalized and Precision Effects of Chinese Medicine: A New System Approach on the Studies of in vivo Prescription Compatibility in Formula Concoction
Steven LOH Cheng Toa, Nanyang Technological University, Singapore
15:05-15:25 Structural Exploration of Different Binding Pockets Suitable to Affect Protein Kinase CK2 with Peptides and Small Molecules
Dirk Lindenblatt, University of Cologne, Germany
15:25-15:45 Total Antioxidant Status in Sapropel Extracts Layer by Layer Aneka Klavina, Rigas Stradinš University, Latvia
15:45-16:05 Chlorophyllin Derivatives Mediated PDT: In Vitro and In Vivo Approaches for Targeted Therapy
Iman Gomaa, October University for Modern Sciences and Arts, Egypt
16:05- Departures
Note: Last minute changes due to functional, private, or organizational needs can be necessary.The event organizer accepts no liability for any additional costs caused by a change of program. Program
is subject to change
United Scientific Group (A Non-profit Organization)
# 8105, Rasor Blvd - Suite #112, PLANO, TX 75024
Ph: +1-469-854-2280/81; Toll Free: +1-844-395-4102; Fax: +1-469-854-2278
Email: [email protected]
Web: https://pharma-rd.com/
We wish to see you in
Los Angeles, CA
Pharma R&D-2020